logo-loader

Shield looking to exploit 'significant' market opportunity after US approval for Feraccru

Published: 09:16 31 Jul 2019 BST

Shield Therapeutics PLC's (LON:STX) Carl Sterritt sat down with Proactive London's Andrew Scott following US regulatory sign-off for their iron deficiency treatment.

The Food & Drug Administration has given broad label approval to Feraccru, which will be marketed as Accrufer in America.

It is already on sale in Europe.

Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst

Proactive Research Analyst Robin Davison speaks to Thomas Warner after publishing a new research note on iron defiency-focused commercial-stage specialty pharmaceutical company Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) Davison gives an overview of what readers can expect from the note,...

on 3/10/23